Israel - English - Ministry of Health

abic marketing ltd, israel - betahistine dihydrochloride - tablets - betahistine dihydrochloride 16 mg - betahistine - betahistine - meniere's syndrom. symptomatic treatment of peripheral vertigo.

Israel - English - Ministry of Health

abic marketing ltd, israel - ibuprofen - suspension - ibuprofen 100 mg / 5 ml - ibuprofen - for the reduction of fever and relief of mild to moderate pain.

Israel - English - Ministry of Health

abic marketing ltd, israel - ibuprofen - suspension - ibuprofen 100 mg / 5 ml - ibuprofen - for the reduction of fever and relief of mild to moderate pain.

Israel - English - Ministry of Health

abic marketing ltd, israel - ibuprofen - suspension - ibuprofen 100 mg / 5 ml - ibuprofen - for the reduction of fever and relief of mild to moderate pain.

Israel - English - Ministry of Health

abic marketing ltd, israel - glimepiride - tablets - glimepiride 2 mg - glimepiride - non-insulin-dependent diabetes mellitus (adult-onset diabetes, type ii diabetes), when diet, regular physical exercise, and weight reduction alone cannot maintain therapeutically suitable blood glucose levels.

Israel - English - Ministry of Health

abic marketing ltd, israel - glimepiride - tablets - glimepiride 3 mg - glimepiride - non-insulin-dependent diabetes mellitus (adult-onset diabetes, type ii diabetes), when diet, regular physical exercise, and weight reduction alone cannot maintain therapeutically suitable blood glucose levels.

Israel - English - Ministry of Health

abic marketing ltd, israel - glimepiride - tablets - glimepiride 4 mg - glimepiride - non-insulin-dependent diabetes mellitus (adult-onset diabetes, type ii diabetes), when diet, regular physical exercise, and weight reduction alone cannot maintain therapeutically suitable blood glucose levels.

Israel - English - Ministry of Health

abic marketing ltd, israel - glimepiride - tablets - glimepiride 1 mg - glimepiride - non-insulin-dependent diabetes mellitus (adult-onset diabetes, type ii diabetes), when diet, regular physical exercise, and weight reduction alone cannot maintain therapeutically suitable blood glucose levels.

Israel - English - Ministry of Health

abic marketing ltd, israel - budesonide micronized; formoterol fumarate dihydrate - powder for inhalation - formoterol fumarate dihydrate 4.5 mcg/dose; budesonide micronized 160 mcg/dose - formoterol and budesonide - asthmaduoresp spiromax 160/4.5 mcg/dose is indicated in adults and adolescents (12 years and older), for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long acting β2 adrenoceptor agonist) is appropriate:patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting β2 adrenoceptor agonists.orpatients already adequately controlled on both inhaled corticosteroids and long acting β2 adrenoceptor-agonists.chronic obstructive pulmonary disease (copd)duoresp spiromax 160/4.5 mcg/dose is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev1)< 70% predicted normal (post-bronchodilator) and an exacerbation history despite regular bronchodilator therapy

Israel - English - Ministry of Health

abic marketing ltd, israel - budesonide micronized; formoterol fumarate dihydrate - powder for inhalation - formoterol fumarate dihydrate 9 mcg/dose; budesonide micronized 320 mcg/dose - formoterol and budesonide - duoresp spiromax 320/9 mcg/dose is indicated in adults and adolescents, age 12 -17 for the regular treatment of asthma where use of a combination (inhaled corticosteroid and long acting β2 adrenoceptor-agonist) is appropriate:-patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting β2 adrenoceptor-agonists.or- patients already adequately controlled on both inhaled corticosteroids and long acting β2 adrenoceptoragonists.chronic obstructive pulmonary disease (copd)duoresp spiromax 320/9 mcg/dose is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in i second (fev1) < 70% predicted normal (post-bronchodilator) and an exacerbation history despite regular bronchodilator therapy